• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Global Monoclonal Antibodies Pipeline Analysis - Product Image

Global Monoclonal Antibodies Pipeline Analysis

  • ID: 2720189
  • January 2014
  • Region: Global
  • 1360 Pages
  • PNS Pharma

The market for monoclonal antibodies (mAB) has become the fastest growing segment of the pharmaceutical industry. In 2012, there were more than 30 monoclonal antibody therapies approved by the FDA which generated annual sales of more than US$ 40 Billion. As the therapeutic mABs already play a significant part in effective medical treatment, it is most likely that their importance would increase by manyfolds in the future.

There has been a continuous rise in the market for therapeutic monoclonal in recent years. In 2012, there were more than 25 monoclonals in US and the EU. Currently, there are about 10 monoclonals which have already achieved category of "blockbuster", that is they are widely used medications that have been able to generate profits of more than US$ 1 Billion (each) to companies that market them.

It has been estimated that in 2012, the global sales of antibody-based therapeutic products was around US$ 55 Billion.

- Global Monoclonal Antibodies Pipeline Analysis - gives comprehensive insight on the various Monoclonal Antibodies based drugs being developed for the treatment of multiple diseases. Research report covers all Monoclonal Antibodies based READ MORE >

1. Global Monoclonal Antibodies Market Overview

2. Monoclonal Antibodies Clinical Development Phase: Unknown
2.1 Overview
2.2 Monoclonal Antibodies Drug Profile in Clinical Phase

3. Monoclonal Antibodies Clinical Development Phase: Research
3.1 Overview
3.2 Monoclonal Antibodies Drug Profile in Clinical Phase

4. Monoclonal Antibodies Clinical Development Phase: Preclinical
4.1 Overview
4.2 Monoclonal Antibodies Drug Profile in Clinical Phase

5. Monoclonal Antibodies Clinical Development Phase: Clinical
5.1 Overview
5.2 Monoclonal Antibodies Drug Profile in Clinical Phase

6. Monoclonal Antibodies Clinical Development Phase: Phase-0
6.1 Overview
6.2 Monoclonal Antibodies Drug Profile in Clinical Phase

7. Monoclonal Antibodies Clinical Development Phase: Phase-I
7.1 Overview
7.2 Monoclonal Antibodies Drug Profile in Clinical Phase

8. Monoclonal Antibodies Clinical Development Phase: Phase-I/II
8.1 Overview
8.2 Monoclonal Antibodies Drug Profile in Clinical Phase

9. Monoclonal Antibodies Clinical Development Phase: Phase-II
9.1 Overview
9.2 Monoclonal Antibodies Drug Profile in Clinical Phase

10. Monoclonal Antibodies Clinical Development Phase: Phase-II/III
10.1 Overview
10.2 Monoclonal Antibodies Drug Profile in Clinical Phase

11. Monoclonal Antibodies Clinical Development Phase: Phase-III
11.1 Overview
11.2 Monoclonal Antibodies Drug Profile in Clinical Phase

12. Monoclonal Antibodies Clinical Development Phase: Preregistration
12.1 Overview
12.2 Monoclonal Antibodies Drug Profile in Clinical Phase

13. Monoclonal Antibodies Clinical Development Phase: Registered
13.1 Overview
13.2 Monoclonal Antibodies Drug Profile in Clinical Phase

14. Marketed
14.1 Overview
14.2 Marketed Monoclonal Antibodies Drug Profile

List Of Tables:

- Alternate Names
- Originator & Owner
- Collaborator
- Technology Provider
- Licensee
- Highest Development Phase
- Indications
- Class
- Mechanism of Action
- ATC code
- Designated Brand Name & Orphan Designation

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos